Will Teva's Restructuring Stop the Bleeding?

Health and Healthcare

Published: November 27, 2017 11:55 am

Last Updated: January 12, 2020 6:01 am

Shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) rose Monday after the company announced a reorganization some of its top leadership positions. This stock has been brutalized in 2017, and while a change like this might sink any other company’s shares, investors are welcoming it at Teva. Maybe this might stop the bleeding.

Excluding Monday’s move, Teva shares had tanked, down 62% year to date, Over the past 52 weeks, the stock is down 64%.

Perhaps the biggest change mentioned was that the company will no longer have two separate global groups for its generic and specialty drug businesses. Instead, Teva will now operate in three regions: North America, Europe and Growth Markets. Each of these regions will manage the entire portfolio — including generics, specialty and over the counter — with full end-to-end profit and loss accountability.

Some of the former global units will be integrated into the new structure, while others will be made redundant.

Also, a newly formed Marketing & Portfolio function will be responsible for overseeing the interface between regions, R&D and operations throughout all product lifecycle stages and optimizing generic and specialty portfolios across the therapeutic areas.

Along with this, there were a few changes to senior leadership. Dr. Michael Hayden, president of global research and development, Dr. Rob Koremans, president and chief executive of global specialty medicines, and Dr. Dipankar Bhattacharjee, president and CEO of global generic medicines group, will be retiring at the end of 2017.

Here are a few of the new faces of the Senior management team, taking effect immediately:

Mike McClellan is appointed executive vice president and chief financial officer and will oversee the Finance Group, Business Development, Investor Relations and Information Technology.

Dr. Hafrun Fridriksdottir is appointed executive vice president of Global R&D.

Brendan O’Grady is appointed executive vice president of North America Commercial.

Richard Daniell is appointed executive vice president of European Commercial, after having served as president and CEO, Teva Generics Europe.

Gianfranco Nazzi is appointed executive vice president of Growth Markets Commercial.

Sven Dethlefs is appointed executive vice president of Global Marketing & Portfolio.

Shares of Teva were last seen up over 5% at $14.35, with a consensus analyst price target of $14.26 and a 52-week range of $10.85 to $38.49.

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps